Nasdaq: $28.36 (+0.24) | AIM: £3.86 (-0.26)
Search
EN
简
繁
About Us
Overview
Corporate Information
Board of Directors
Senior Management
Contact Us
What We Do
Overview
Research and Development
Commercialization
Other Ventures
Key Corporate Partnerships
Pipeline & Products
Overview
Our Products
Our Pipeline
Expanded Access
News & Presentations
Recent News
All RNS & Press Releases
Presentations & Publications
Mailing List Sign-up
Shareholder Information
Overview
Events, Circulars & Forms
Share Price & Chart
Major Shareholders
Financial Reports
SEC Filings
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Warning to Shareholders
Terms of Reference & Policies
AIM Rule 26
Careers
About Us
Overview
Corporate Information
Board of Directors
Senior Management
Contact Us
What We Do
Overview
Research and Development
Commercialization
Other Ventures
Key Corporate Partnerships
Pipeline & Products
Overview
Our Products
Our Pipeline
Expanded Access
News & Presentations
Recent News
All RNS & Press Releases
Presentations & Publications
Mailing List Sign-up
Shareholder Information
Overview
Events, Circulars & Forms
Share Price & Chart
Major Shareholders
Financial Reports
SEC Filings
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Warning to Shareholders
Terms of Reference & Policies
Audit Committee – Terms of Reference
AIM Rule 26
Careers
News & Presentations
Chi-Med
News & Presentations
| Presentations
Previous Article
|
Next Article
Presentations
,
Scientific Publications
| 23 Dec 2014
Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1,2,3 tyrosine kinases for cancer therapy (Cancer Biology & Therapy 2014)
1 items
View Publication (PDF)